A prostate stem cell antigen-derived peptide immunogenic in HLA-A24− prostate cancer patients
Version of Record online: 2 FEB 2004
Copyright © 2004 Wiley-Liss, Inc.
Volume 60, Issue 3, pages 205–213, 1 August 2004
How to Cite
Matsueda, S., Yao, A., Ishihara, Y., Ogata, R., Noguchi, M., Itoh, K. and Harada, M. (2004), A prostate stem cell antigen-derived peptide immunogenic in HLA-A24− prostate cancer patients. Prostate, 60: 205–213. doi: 10.1002/pros.20038
- Issue online: 28 MAY 2004
- Version of Record online: 2 FEB 2004
- Manuscript Accepted: 2 DEC 2003
- Manuscript Received: 7 OCT 2003
- Ministry of Health, Labor, and Welfare of Japan (for Cancer Research (15–17))
- Ministry of Education, Science, Sports, and Culture of Japan
- prostate cancer;
- cytotoxic T lymphocytes;
We attempted to identify prostate stem cell antigen (PSCA)-derived peptides immunogenic in HLA-A24+ prostate cancer patients.
Peripheral blood mononuclear cells (PBMCs) were stimulated in vitro with each of three different PSCA-derived peptides, which were prepared based on the HLA-A24 binding motif, and their peptide-specific and HLA-A24-restricted anti-tumor responses were examined. Plasma levels of immunoglobulin G (IgG) against PSCA peptides were measured by enzyme-linked immunosorbent assay (ELISA).
Among three PSCA peptides, the PSCA 76–84 peptide most effectively induced peptide-specific cytotoxic T lymphocytes (CTLs) from PBMCs of HLA-A24+ prostate cancer patients. Cytotoxicity was dependent on peptide-specific and CD8+ T cells. The PSCA 76–84 peptide-stimulated PBMCs showed a significant level of cytotoxicity against prostate cancer cells in an HLA-A24-restricted manner. IgG reactive to the PSCA 76–84 peptide was detected in half of patients.
The PSCA 76–84 peptide should be considered for use in clinical trials of immunotherapy for HLA-A24+ patients. © 2004 Wiley-Liss, Inc.